220 related articles for article (PubMed ID: 15308561)
1. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction.
Colucci S; Brunetti G; Rizzi R; Zonno A; Mori G; Colaianni G; Del Prete D; Faccio R; Liso A; Capalbo S; Liso V; Zallone A; Grano M
Blood; 2004 Dec; 104(12):3722-30. PubMed ID: 15308561
[TBL] [Abstract][Full Text] [Related]
2. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
Brunetti G; Colucci S; Rizzi R; Mori G; Colaianni G; Oranger A; Zallone A; Liso V; Grano M
Ann N Y Acad Sci; 2006 Apr; 1068():334-40. PubMed ID: 16831934
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
Emery JG; McDonnell P; Burke MB; Deen KC; Lyn S; Silverman C; Dul E; Appelbaum ER; Eichman C; DiPrinzio R; Dodds RA; James IE; Rosenberg M; Lee JC; Young PR
J Biol Chem; 1998 Jun; 273(23):14363-7. PubMed ID: 9603945
[TBL] [Abstract][Full Text] [Related]
5. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
6. T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients.
Brunetti G; Colucci S; Pignataro P; Coricciati M; Mori G; Cirulli N; Zallone A; Grassi FR; Grano M
J Periodontol; 2005 Oct; 76(10):1675-80. PubMed ID: 16253089
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.
Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K
Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863
[TBL] [Abstract][Full Text] [Related]
8. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival.
Pritzker LB; Scatena M; Giachelli CM
Mol Biol Cell; 2004 Jun; 15(6):2834-41. PubMed ID: 15064358
[TBL] [Abstract][Full Text] [Related]
9. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis.
Collin-Osdoby P; Rothe L; Anderson F; Nelson M; Maloney W; Osdoby P
J Biol Chem; 2001 Jun; 276(23):20659-72. PubMed ID: 11274143
[TBL] [Abstract][Full Text] [Related]
10. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
[TBL] [Abstract][Full Text] [Related]
11. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
13. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T
Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720
[TBL] [Abstract][Full Text] [Related]
14. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
15. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
16. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm.
Lonergan M; Aponso D; Marvin KW; Helliwell RJ; Sato TA; Mitchell MD; Chaiwaropongsa T; Romero R; Keelan JA
J Clin Endocrinol Metab; 2003 Aug; 88(8):3835-44. PubMed ID: 12915677
[TBL] [Abstract][Full Text] [Related]
18. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
19. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
